Thomas John C

Average Profitability
<0.0001%
Insider Buys Quantity
1
Insider Buys Sum
$5,650.00
Insider Sells Quantity
14
Insider Sells Sum
$1.86M

Insider Activity of Thomas John C

The largest purchase of all time was on 2022-01-04 and amounted to 1000 shares of Virios Therapeutics, Inc. for $5,650.

The largest sale of all time was on 2020-12-10 and amounted to 42592 shares of ImmunityBio, Inc. for $461,122.

Biography of Thomas John C

No biography is available at this moment.

2022-01-04PurchaseVirios Therapeutics, Inc.
VIRI
director
1,000
0.0119%
$5.65$5,650-22.81%
2020-12-10SaleImmunityBio, Inc.
IBRX
director
42,592
0.0385%
$10.83$461,122+25.09%
2020-08-19SaleImmunityBio, Inc.
IBRX
director
20,000
0.0054%
$9.19$183,800+55.1%
2020-08-13SaleImmunityBio, Inc.
IBRX
director
40,000
0.0106%
$9.41$376,600+49.08%
2020-08-11SaleImmunityBio, Inc.
IBRX
director
20,000
0.0057%
$10.35$207,042+46.4%
2019-12-16SaleImmunityBio, Inc.
IBRX
director
10,000
0.01%
$3.14$31,400+119.44%
2019-12-13SaleImmunityBio, Inc.
IBRX
director
20,000
0.0193%
$2.73$54,600+140.8%
2019-12-12SaleImmunityBio, Inc.
IBRX
director
10,000
0.0092%
$1.99$19,918+213.98%
2019-09-09SaleImmunityBio, Inc.
IBRX
director
13,956
0.0136%
$1.24$17,305+225.58%
2019-09-06SaleImmunityBio, Inc.
IBRX
director
7,080
0.0073%
$1.24$8,779+236.48%
2019-09-05SaleImmunityBio, Inc.
IBRX
director
2,964
0.003%
$1.25$3,705+223.2%
2017-06-20SaleImmunityBio, Inc.
IBRX
director
40,000
0.0493%
$7.46$298,500-37.82%
2016-11-25SaleImmunityBio, Inc.
IBRX
director
6,168
0.0076%
$7.50$46,260-28.78%
2016-11-23SaleImmunityBio, Inc.
IBRX
director
7,719
0.0094%
$7.50$57,893-28.61%
2016-11-22SaleImmunityBio, Inc.
IBRX
director
13,000
0.016%
$7.50$97,500-28.32%
Company
About Prismo.proPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.